Walleye Capital’s Avita Medical RCEL Stock Holding History

Walleye Capital’s Portfolio RCEL Stock Details RCEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-50,500	Closed	-$738K	–	5409
2023 Q3	$738K	Buy	+50,500	New	+$855K	﹤0.01%	2493
2022 Q3	–	Sell	-13,657	Closed	-$65K	–	3482
2022 Q2	$65K	Sell	13,657 -2,263	-14%	-$14K	﹤0.01%	1797
2022 Q1	$135K	Buy	+15,920	New	+$147K	﹤0.01%	1661

Other funds holding RCEL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Walleye Capital's RCEL Position: Q4 2023 in Review

Walleye Capital sold out of Avita Medical (RCEL) in Q4 2023, closing a stake of 50,500 shares — an estimated $738K sold.

Walleye Capital first reported a position in RCEL in Q1 2022 and held it in 3 quarters. The position peaked at $738K in Q3 2023. 84 funds tracked by Wall St. Rank hold RCEL as of Q4 2023.

Walleye Capital reported no remaining Avita Medical position as of Q4 2023 after selling out during the quarter.
Walleye Capital sold 50,500 Avita Medical shares in Q4 2023, an estimated $738K.
Walleye Capital first reported a position in Avita Medical in Q1 2022 and held it in 3 quarters.
Walleye Capital's Avita Medical position peaked at $738K in Q3 2023.
84 funds tracked by Wall St. Rank held Avita Medical as of Q4 2023.

Based on Walleye Capital's 13F filing for Q4 2023, filed 14 Feb 2024.